With a cancer vaccine and checkpoint inhibitor approved, immunotherapy for prostate cancer offers new hope to patients with advanced prostate cancer.
Learn about detection, diagnostic approaches, treatment options and advances for prostate cancer, including robotic prostatectomy and current research.
What’s new in the treatment of prostate cancer with immunotherapy? Urologic oncologist Bilal Siddiqui, M.D., weighs in.
The immune system has the remarkable ability to kills cells that can cause harm, such as infected cells or cancer cells. However, in most patients with progressing cancer, anti-cancer immune responses either never developed or have been turned off by the cancer. One way to fight cancer is to hack the immune system, retraining immune cells to respond to the malfunctioning cancer cells. Sipuleucel-T (Provenge®) is a cell-based prostate cancer vaccine that has been approved by the FDA for men wit...
Cancer vaccine ; Sipuleucel-T (Provenge) is a cancer vaccine. Unlike traditional vaccines, which boost the body’s immune system to help prevent infections, this vaccine boosts the immune system to help it attack prostate cancer cells. The vaccine is used to treat advanced prostate cancer that's no longer responding to hormone therapy but that is causing few or no symptoms. This vaccine is made specifically for each man. To make it, white blood cells (cells of the immune system) are removed from your blood over a few hours while you are hooked ...
Cancer immunotherapy Peptide epitope of CD20 bound to rituximab's FAB Specialty immuno... Currently, only one vaccine (sipuleucel-T for prostate cancer) has been approved. In cell-mediated...
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.In this double...
The only FDA-approved immunotherapy for prostate cancer is the dendritic-cell-based agent Sipuleucel-T, which yielded an advantage in overall survival, but not in progression-free survival...
Immunotherapy has the potential to change the way all cancer types are treated and cured. Learn about Immunotherapy by cancer type.
The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, co...